Background: It has been shown that serotonin (5-hydroxytryptamine, 5-HT) is involved in exacerbating vascular abnormalities; however, its role in mediating changes in cardiac function due to myocardial injury has yet to be established. This study examined the effect of sarpogrelate, a 5-HT2A receptor blocker, in preventing cardiac dysfunction due to myocardial infarction (MI).
Methods and Results: Rats were treated 3 days before surgery with or without 5 mg.kg-1.day-1 sarpogrelate, and the left coronary artery was ligated for 3 weeks to induce MI. Sarpogrelate reduced the mortality from 40% to 30%, infarct size from 35% to 25%, and left ventricular end diastolic pressure from 15 mm Hg to 10 mm Hg in MI rats. Electrocardiographic (ECG) tracings showed a marked deviation in the ST-segment and prolongation of the QTc interval in MI rats during the 3 weeks; these changes were attenuated by sarpogrelate pretreatment. In another set of experiments, MI rats were treated with 5 mg.kg-1.day-1 sarpogrelate 1 hour after the surgery, and the hemodynamic and electrocardiograph changes were assessed at 3 weeks. This posttreatment was also found to reduce infarct size, improve cardiac function, and attenuate ECG changes.
Conclusions: Sarpogrelate attenuates cardiac dysfunction, infarct size, and changes in the ECG due to MI. These results also support the view that serotonin and 5-HT2A may contribute to the deleterious effects of ischemic injury in the heart.
1. Rappaport RM, Green AA, Page IH. Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J Biol Chem176:1243-1251, 1948
2.
2. Vikenes K, Farstad M, Nordrehaug JE. Serotonin is associated with coronary artery disease and cardiac events. Circulation100:483-489, 1999
3.
3. Parikh V, Singh M. Resident cardiac mast cells and the cardioprotective effect of ischemic preconditioning in isolated rat heart. J Cardiovasc Pharmacol30:149-156, 1997
4.
4. Saxena PR. Cardiovascular effects from stimulation of 5-hydroxytryptamine receptors. Fund Clin Pharmacol3:245-265, 1989
5.
5. Nilsson T, Longmore J, Shaw D, et al. Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol372:49-56, 1999
6.
6. Fozard JR, Mwaluko GM. Mechanism of the indirect sympathomimetic effect of 5-hydroxytryptamine on the isolated heart of the rabbit. Br J Pharmacol57:115-125, 1976
7.
7. Sakai K, Akima M. An analysis of the stimulant effects of 5-hydroxytryptamine on isolated, blood-perfused rat heart. Eur J Pharmacol55:421-424, 1979
8.
8. Hamamori Y, Yokoyama M, Yamada M, Akita H, Goshima K, Fukuzaki H. 5-Hydroxytryptamine induces phospholipase C-mediated hydrolysis of phosphoinositides through 5-hydroxytryptamine-2 receptors in cultured fetal mouse ventricular myocytes. Circ Res66:1474-1483, 1990
9.
9. Laer S, Remmers F, Scholz H, Stein B, Muller FU, Neumann J. Receptor mechanisms involved in the 5-HTinduced inotropic action in the rat isolated atrium. Br J Pharmacol123:1182-1188, 1998
10.
10. Brogden RN, Sorkin EM. Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. Drugs40:903-949, 1990
11.
11. Grover GJ, Sargent CA, Dzwonczyk S, Normandin DE, Antonaccio MJ. Protective effect of serotonin (5-HT2) receptor antagonists in ischemic rat hearts. J Cardiovasc Pharmacol22:664-672, 1993
12.
12. Takada Y, Takada A, Urano T. MCI-9042, the new selective antagonist of serotonergic (5-HT2A) receptors. Cardiovasc Drug Reviews15:101-121, 1997
13.
13. Tamura K, Kanzaki T, Saito Y, Otabe M, Morisaki N. Serotonin (5-hydroxytryptamine, 5-HT) enhances migration of rat aortic smooth muscle cells through 5-HT2 receptors. Atherosclerosis132:139-143, 1997
14.
14. Sharma SK, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla NS. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther290:1475-1481, 1999
15.
15. Miyata K, Shimokawa H, Higo T, et al. Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. J Cardiovasc Pharmacol35:294-301, 2000
16.
16. Temsah RM, Kumamoto H, Takeda N, Dhalla NS. Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart. Can J Physiol Pharmacol79:761-767, 2001
17.
17. Ogawa S, Takeuchi K, Sugimura K, et al. The 5-HT2receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients. Clin Exp Pharmacol Physiol26:461-464, 1999
18.
18. Tanaka T, Fujita M, Nakae I, et al. Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. J Am Coll Cardiol32:1982-1986, 1998
19.
19. Dixon IMC, Lee SL, Dhalla NS. Nitrendipine binding in congestive heart failure due to myocardial infarction. Circ Res66:782-788, 1990
20.
20. Ren B, Lukas A, Shao Q, et al. Electrocardiographic changes and mortality due to myocardial infarction in rats with or without imidapril treatment. J Cardiovasc Pharmacol Therapeut3:11-22, 1998
21.
21. van den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation79:116-124, 1989
22.
22. Sharma SK, Del Rizzo DF, Zahradka P, et al. Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: Implications for longterm graft patency. Ann Thorac Surg71:1856-1865, 2001
23.
23. Knowles ID, Ramage AG. Evidence for a role for central 5-HT2B as well as 5-HT2A receptors in cardiovascular regulation in anaesthetized rats. Br J Pharmacol128:530-542, 1999
24.
24. Saydoff JA, Rittenhouse PA, Carnes M, Armstrong J, Van De Kar LD, Brownfield MS. Neuroendocrine and cardiovascular effects of serotonin: Selective role of brain angiotensin on vasopressin. Am J Physiol Endocrinol Metab270:E513-E521, 1996
25.
25. Pawlak D, Adamkiewicz M, Malyszko J, Takada A, Mysliwiec M, Buczko W. Vascular and cardiac effects of DV-7028, a selective, 5-HT2-receptor antagonist in rats. J Cardiovasc Pharmacol32:266-273, 1998
26.
26. Xie Z, Gao M, Batra S, Koyama T. The capillarity of left ventricular tissue of rats subjected to coronary artery occlusion. Cardiovasc Res33:671-676, 1997
27.
27. Schlapfer H, Maeder JP, Friedemann M. Significance of reciprocal ST-segment depression in the acute stage of transmural myocardial infarct. Schweiz Med Wochenschr116:1840-1847, 1986
28.
28. Clusin WT, Buchbinder M, Harrison DC. Calcium overload, “injury” current and early ischemic cardiac arrhythmias-a direct connection. Lancet1:272-274, 1983
29.
29. Janse MJ. ST segment mapping and infarct size. Cardiovasc Res45:190-193, 2000
30.
30. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol72:23B-25B, 1993
31.
31. Ahnve S, Gilpin E, Madsen EB, Froelicher V, Henning H, Ross J Jr.Prognostic importance of QTc interval at discharge after acute myocardial infarction: A multicenter study of 865 patients. Am Heart J108:395-400, 1984
32.
32. Cameron HA, Waller PC, Ramsay LE. Ketanserin in essential hypertension: Use as monotherapy and in combination with a diuretic or P-adrenoceptor antagonist. Br J Clin Pharmacol24:705-711, 1987
33.
33. Zehender M, Meinertz T, Hohnloser S, et al. Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Am J Cardiol63:826-832, 1989
34.
34. Kamiya K, Venkatesh N, Singh BN. Acute and chronic effects of ketanserin on the electrophysiologic properties of isolated rabbit ventricular myocardium: Particular reference to repolarization. Am Heart J115:1222-1228, 1988
35.
35. Le Grand B, Talmant J-M, Rieu J-P, Patoiseau J-F, Colpaert FC, John GW. Investigation of the mechanism by which ketanserin prolongs the duration of the cardiac action potential. J Cardiovasc Pharmacol26:803-809, 1995
